Cardiovascular Health

The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.
[[thumbnail_alt_text]]
A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events. 
[[thumbnail_alt_text]]
Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.
[[thumbnail_alt_text]]
A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.
[[thumbnail_alt_text]]
The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.
[[thumbnail_alt_text]]
Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.
[[thumbnail_alt_text]]
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
[[thumbnail_alt_text]]
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
[[thumbnail_alt_text]]
The prevalence of the issue in the United States ranges from 2.7 million to 6.1 million, and this number is expected to increase to 12.1 million by 2030.